FinTrust Capital Advisors’s TG Therapeutics TGTX Stock Holding History

FinTrust Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$19K	–	1212
2021 Q2	$19K	Hold	500	–	–	0.01%	777
2021 Q1	$24K	Hold	500	–	–	0.01%	673
2020 Q4	$26K	Hold	500	–	–	0.01%	617
2020 Q3	$13	Buy	+500	New	+$11.5K	﹤0.01%	742

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's TGTX Position: Q3 2021 in Review

FinTrust Capital Advisors sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 500 shares — an estimated $19K sold.

FinTrust Capital Advisors first reported a position in TGTX in Q3 2020 and held it in 4 quarters. The position peaked at $26K in Q4 2020. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

FinTrust Capital Advisors reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
FinTrust Capital Advisors sold 500 TG Therapeutics shares in Q3 2021, an estimated $19K.
FinTrust Capital Advisors first reported a position in TG Therapeutics in Q3 2020 and held it in 4 quarters.
FinTrust Capital Advisors's TG Therapeutics position peaked at $26K in Q4 2020.
222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on FinTrust Capital Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.